Stay updated on PAAP for Pralsetinib in NSCLC and MTC Clinical Trial

Sign up to get notified when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    22 days ago
    Change Detected
    Summary
    Footer now shows Revision: v3.3.3, and items referencing HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed.
    Difference
    0.2%
    Check dated 2025-12-23T13:47:06.000Z thumbnail image
  4. Check
    29 days ago
    No Change Detected
  5. Check
    50 days ago
    Change Detected
    Summary
    The page now shows a new revision label: v3.3.2 replaces the previous v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T20:54:21.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    Removed the government funding status notice banner at the top of the page; the study details, eligibility criteria, and contacts remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.6%
    Check dated 2025-11-17T18:17:36.000Z thumbnail image
  7. Check
    72 days ago
    Change Detected
    Summary
    The page layout has been updated visually, but the study details and eligibility criteria remain unchanged.
    Difference
    0.2%
    Check dated 2025-11-03T12:48:15.000Z thumbnail image
  8. Check
    100 days ago
    Change Detected
    Summary
    Updated version to v3.2.0 and removed a specific resource topic (Medullary thyroid carcinoma) from the Genetic and Rare Diseases Information Center resources; added a government operating-status notice.
    Difference
    6%
    Check dated 2025-10-06T04:24:18.000Z thumbnail image
  9. Check
    107 days ago
    Change Detected
    Summary
    Renamed a medical condition term (Medullary thyroid gland carcinoma → Medullary thyroid carcinoma) and updated the revision/version to v3.1.0.
    Difference
    0.2%
    Check dated 2025-09-28T23:59:46.000Z thumbnail image

Stay in the know with updates to PAAP for Pralsetinib in NSCLC and MTC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.